216 related articles for article (PubMed ID: 32747603)
1. Low-Avidity Autoantibodies against Bactericidal/Permeability-Increasing Protein Occur in Gram-Negative and Gram-Positive Bacteremia.
Theprungsirikul J; Thaden JT; Wierzbicki RM; Burns AS; Skopelja-Gardner S; Fowler VG; Winthrop KL; Martin IW; Rigby WFC
Infect Immun; 2020 Sep; 88(10):. PubMed ID: 32747603
[TBL] [Abstract][Full Text] [Related]
2. Dissociation of systemic and mucosal autoimmunity in cystic fibrosis.
Theprungsirikul J; Skopelja-Gardner S; Meagher RE; Clancy JP; Zemanick ET; Ashare A; Rigby WFC
J Cyst Fibros; 2020 Mar; 19(2):196-202. PubMed ID: 31262645
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization.
Aebi C; Theiler F; Aebischer CC; Schoeni MH
Pediatr Infect Dis J; 2000 Mar; 19(3):207-12. PubMed ID: 10749460
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against bactericidal/permeability-increasing protein (BPI) in children with acute pneumonia.
Steiner P; Otth M; Casaulta C; Aebi C
FEMS Immunol Med Microbiol; 2009 Nov; 57(2):125-8. PubMed ID: 19702878
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal/Permeability-Increasing Protein Preeminently Mediates Clearance of
Theprungsirikul J; Skopelja-Gardner S; Burns AS; Wierzbicki RM; Rigby WFC
Front Immunol; 2021; 12():659523. PubMed ID: 33981306
[TBL] [Abstract][Full Text] [Related]
6. Scorpionfish BPI is highly active against multiple drug-resistant
Holzinger JM; Toelge M; Werner M; Ederer KU; Siegmund HI; Peterhoff D; Blaas SH; Gisch N; Brochhausen C; Gessner A; Bülow S
Elife; 2023 Jul; 12():. PubMed ID: 37461324
[TBL] [Abstract][Full Text] [Related]
7. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.
Mahadeva R; Dunn AC; Westerbeek RC; Sharples L; Whitehouse DB; Carroll NR; Ross-Russell RI; Webb AK; Bilton D; Lomas DA; Lockwood CM
Clin Exp Immunol; 1999 Sep; 117(3):561-7. PubMed ID: 10469063
[TBL] [Abstract][Full Text] [Related]
8. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
Schultz H; Csernok E; Schuster A; Schmitz TS; Ernst M; Gross WL
Pediatr Allergy Immunol; 2000 May; 11(2):64-70. PubMed ID: 10893006
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies.
Carlsson M; Eriksson L; Erwander I; Wieslander J; Segelmark M
Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S95-100. PubMed ID: 14740434
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.
Zhao MH; Jayne DR; Ardiles LG; Culley F; Hodson ME; Lockwood CM
QJM; 1996 Apr; 89(4):259-65. PubMed ID: 8733512
[TBL] [Abstract][Full Text] [Related]
11. The role for neutrophil extracellular traps in cystic fibrosis autoimmunity.
Skopelja S; Hamilton BJ; Jones JD; Yang ML; Mamula M; Ashare A; Gifford AH; Rigby WF
JCI Insight; 2016 Oct; 1(17):e88912. PubMed ID: 27777975
[TBL] [Abstract][Full Text] [Related]
12. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI).
Schultz H
Autoimmun Rev; 2007 Mar; 6(4):223-7. PubMed ID: 17317612
[TBL] [Abstract][Full Text] [Related]
13. BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.
Schultz H; Schinke S; Weiss J; Cerundolo V; Gross WL; Gadola S
Clin Exp Immunol; 2003 Aug; 133(2):252-9. PubMed ID: 12869032
[TBL] [Abstract][Full Text] [Related]
14. Autoimmunity to bactericidal/permeability-increasing protein in bronchiectasis exhibits a requirement for
Skopelja-Gardner S; Theprungsirikul J; Meagher RE; Beliveau CM; Bradley KE; Avery M; Henkle E; Siegel S; Gifford AH; Winthrop KL; Rigby WFC
Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30385530
[No Abstract] [Full Text] [Related]
15. BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients.
Lindberg U; Carlsson M; Hellmark T; Segelmark M
J Immunol Res; 2015; 2015():947934. PubMed ID: 26273683
[TBL] [Abstract][Full Text] [Related]
16. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL
Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
[TBL] [Abstract][Full Text] [Related]
17. BPI-ANCA is expressed in the airways of cystic fibrosis patients and correlates to platelet numbers and Pseudomonas aeruginosa colonization.
Hovold G; Lindberg U; Ljungberg JK; Shannon O; Påhlman LI
Respir Med; 2020; 170():105994. PubMed ID: 32843162
[TBL] [Abstract][Full Text] [Related]
18. Extensive endoscopic image-guided sinus surgery decreases BPI-ANCA in patients with cystic fibrosis.
Aanaes K; Rasmussen N; Pressler T; Segelmark M; Johansen HK; Lindberg U; Høiby N; Carlsson M; Wieslander J; Buchwald C
Scand J Immunol; 2012 Dec; 76(6):573-9. PubMed ID: 22946777
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease.
Carlsson M; Shukla S; Petersson AC; Segelmark M; Hellmark T
J Cyst Fibros; 2011 Jul; 10(4):265-71. PubMed ID: 21463973
[TBL] [Abstract][Full Text] [Related]
20. BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study.
Lindberg U; Carlsson M; Löfdahl CG; Segelmark M
Clin Dev Immunol; 2012; 2012():370107. PubMed ID: 23346184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
